• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

    1/8/26 8:15:55 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDYA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    IDEAYA Biosciences, Inc.

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    45166A102

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    Federated Hermes, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,395,771.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,395,771.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,395,771.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.87 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    Voting Shares Irrevocable Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,395,771.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,395,771.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,395,771.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.87 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    Thomas R. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,395,771.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,395,771.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,395,771.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.87 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    Ann C. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,395,771.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,395,771.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,395,771.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.87 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    J. Christopher Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,395,771.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,395,771.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,395,771.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.87 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IDEAYA Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    5000 Shoreline Ct, Suite 300, South San Francisco, CA 94080
    Item 2. 
    (a)Name of person filing:

    Federated Hermes, Inc.
    (b)Address or principal business office or, if none, residence:

    1001 Liberty Avenue, Pittsburgh, PA 15222-3779
    (c)Citizenship:

    Pennsylvania
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    45166A102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit "1" Attached
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Federated Hermes, Inc.
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as President of Federated Hermes, Inc.
    Date:01/08/2026
     
    Voting Shares Irrevocable Trust
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:01/08/2026
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:01/08/2026
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:01/08/2026
     
    Thomas R. Donahue
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue
    Date:01/08/2026
     
    Ann C. Donahue
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue
    Date:01/08/2026
     
    J. Christopher Donahue
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue
    Date:01/08/2026

    Comments accompanying signature:  SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY
    Get the next $IDYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDYA

    DatePrice TargetRatingAnalyst
    1/7/2026$50.00Buy
    UBS
    11/24/2025Buy
    Truist
    9/18/2025$50.00Buy
    Guggenheim
    9/4/2025$40.00Overweight
    Barclays
    9/4/2025$41.00Mkt Outperform
    Citizens JMP
    7/22/2025Buy
    TD Cowen
    7/10/2025$25.00Neutral
    Goldman
    6/26/2025$44.00Overweight
    Wells Fargo
    More analyst ratings

    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on IDEAYA Biosciences with a new price target

    UBS resumed coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00

    1/7/26 9:46:25 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on IDEAYA Biosciences

    Truist initiated coverage of IDEAYA Biosciences with a rating of Buy

    11/24/25 8:30:36 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on IDEAYA Biosciences with a new price target

    Guggenheim initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00

    9/18/25 8:43:36 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bleharski Joshua

    3 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    6/27/25 4:20:15 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Yarno Wendy L

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    6/26/25 4:57:37 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Stein Jeffrey

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    6/26/25 4:56:47 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare Conference. 44th Annual J.P. Morgan Healthcare ConferenceMonday, January 12th, 2026, at 3:45 PM PT (6:45 PM ET) Presentation by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. MorganA

    1/5/26 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

    Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trialTopline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United StatesSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first lin

    12/11/25 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

    Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE574, a potential first-in-class KAT6/7 dual inhibitor with high selectivity over related KAT5/8 enzymes. The company is targeting to begin a Phase 1 dose escalation trial of monotherap

    12/10/25 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

    SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    1/8/26 8:15:55 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by IDEAYA Biosciences Inc.

    8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

    12/12/25 4:05:41 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by IDEAYA Biosciences Inc.

    8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

    12/5/25 4:19:17 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer.  Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. 

    2/10/25 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

    Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.

    11/18/24 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Financials

    Live finance-specific insights

    View All

    IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

    Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss

    9/23/24 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.

    9/22/24 9:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

    ~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-

    7/8/24 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 4:23:02 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 3:13:37 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 1:22:38 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care